MDNA.F Stock Overview
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medicenna Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.27 |
| 52 Week High | CA$1.56 |
| 52 Week Low | CA$0.15 |
| Beta | 1.33 |
| 1 Month Change | 10.72% |
| 3 Month Change | 284.85% |
| 1 Year Change | 105.10% |
| 3 Year Change | -67.10% |
| 5 Year Change | 131.33% |
| Change since IPO | -15.10% |
Recent News & Updates
Recent updates
Medicenna extends period to exercise certain warrants
Sep 30Medicenna, Merck enter clinical trial collaboration to evaluate combo cancer treatment
Sep 13Medicenna Therapeutics GAAP EPS of -$0.07 in-line
Aug 15Medicenna Therapeutics stock slides on launch of units offering
Aug 08Medicenna Therapeutics reports FY results
May 28Medicenna posts positive data from mid-stage brain cancer study
May 07Medicenna announces ATM sales facility for $25M
Dec 31Medicenna Therapeutics reports Q2 results
Nov 13Shareholder Returns
| MDNA.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.4% | -4.2% | -3.7% |
| 1Y | 105.1% | -2.0% | 20.5% |
Return vs Industry: MDNA.F exceeded the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: MDNA.F exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| MDNA.F volatility | |
|---|---|
| MDNA.F Average Weekly Movement | 21.4% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MDNA.F's share price has been volatile over the past 3 months.
Volatility Over Time: MDNA.F's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 16 | Fahar Merchant | www.medicenna.com |
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors.
Medicenna Therapeutics Corp. Fundamentals Summary
| MDNA.F fundamental statistics | |
|---|---|
| Market cap | US$92.81m |
| Earnings (TTM) | -US$11.17m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.8x
P/E RatioIs MDNA.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDNA.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$15.42m |
| Earnings | -CA$15.42m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MDNA.F perform over the long term?
See historical performance and comparison